1. Executive Summary 2. United States Carrier Screening Volume & Forecast (2015 - 2026) 3. United States Carrier Screening Market Size & Forecast (2015 – 2026) 4. Key Drivers and Inhibitors of the United States Carrier Screening Market 4.1 Market Drivers 4.2 Inhibitors 5. Reimbursement Policies of the United States Carrier Screening 6. Regulation System of the United States Carrier Screening 7. Major Deals in the Carrier Screening Market 7.1 Collaboration Deals 7.2 Merger and Acquisitions 7.3 Distribution Agreement 7.4 Partnership Deals 8. Key Companies Analysis 8.1 Natera 8.1.1 Business Overview 8.1.2 Carrier Screening Test Portfolio 8.1.3 Carrier Screening - Latest Development & Trends 8.2 Myraid Genetics 8.2.1 Business Overview 8.2.2 Carrier Screening Portfolio 8.2.3 Carrier Screening - Latest Development & Trends 8.3 Luminex Corporation 8.3.1 Business Overview 8.3.2 Carrier Screening Portfolios 8.3.3 Carrier Screening – Latest Development & Trends 8.4 Integrated Genetics (LapCorp) 8.4.1 Business Overview 8.4.2 Carrier Screening Portfolios 8.4.3 Carrier Screening – Latest Development & Trends 8.5 Quest Diagnostics 8.5.1 Business Overview 8.5.2 Carrier Screening Portfolios 8.5.3 Carrier Screening – Latest Development & Trends 8.6 Thermo Fisher Scientific Inc. 8.6.1 Business Overview 8.6.2 Carrier Screening Portfolios 8.6.3 Carrier Screening – Latest Development & Trends 8.7 Centogene 8.7.1 Business Overview 8.7.2 Carrier Screening Portfolios 8.7.3 Carrier Screening – Latest Development & Trends 8.8 Invitae Corporation 8.8.1 Business Overview 8.8.2 Carrier Screening Portfolios 8.8.3 Carrier Screening – Latest Development & Trends 8.9 Otogenetics 8.9.1 Business Overview 8.9.2 Carrier Screening Portfolios 8.9.3 Carrier Screening – Latest Development & Trends 8.10 GenPath 8.10.1 Business Overview 8.10.2 Carrier Screening Portfolios 8.10.3 Carrier Screening – Latest Development & Trends 8.11 Progenity 8.11.1 Business Overview 8.11.2 Carrier Screening Portfolios 8.11.3 Carrier Screening – Latest Development & Trends 8.12 Fulgent Genetics 8.12.1 Business Overview 8.12.2 Carrier Screening Portfolios 8.12.3 Carrier Screening – Latest Development & Trends 8.13 GenMark Diagnostics 8.13.1 Business Overview 8.13.2 Carrier Screening Portfolios 8.13.3 Carrier Screening – Latest Development & Trends 8.14 Sema4 8.14.1 Business Overview 8.14.2 Carrier Screening Portfolios 8.14.3 Carrier Screening – Latest Development & Trends 8.15 Pathway Genomics 8.15.1 Business Overview 8.15.2 Carrier Screening Portfolios 8.15.3 Carrier Screening – Latest Development & Trends 8.16 Gene By Gene 8.16.1 Business Overview 8.16.2 Carrier Screening Portfolios 8.16.3 Carrier Screening – Latest Development & Trends

Table 6–1: Collaboration Deals in the Carrier Screening Market Table 6–2: Merger and Acquisition in the Carrier Screening Market Table 6–3: Distribution Agreementin the Carrier Screening Market Table 6–4: Partnerships Deals in the Carrier Screening Market Table 7–1: CentoScreen Testing Options Figure 2–1: United States Carrier Screening Volume (Number),2015 – 2018 Figure 2–2: United States Carrier Screening Volume Forecast (Number),2019 – 2026 Figure 3–1: United States Carrier Screening Market (Million US$),2015 – 2018 Figure 3–2: United States Carrier Screening Market Forecast (Million US$),2019 – 2026

Natera, Myriad Genetics, Luminex Corporation, Integrated Genetics (LabCorp), Quest Diagnostics, Thermo Fisher Scientific Inc, Centogene, Invitae Corporation, Otogenetics, GenPath, Progenity, Fulgent Genetics, GenMark Diagnostics, Sema4, Pathway Genomics and Gene By Gene